Enhancer heterogeneity of lung carcinoids reveals sensitivity to FGF signaling inhibition

#3961

Introduction: Well-differentiated low grade lung carcinoids are histo-pathologically classified as typical and atypical, but each subtype is still heterogenous both at the molecular level and its clinical manifestation. Therefore, the treatment of these patients is challenging. The two main challenges are the lack of effective drug treatments and the lack of reliable biomarkers to guide management since the disease in patients with the same tumor grade/stage often has different clinical courses. The genetic, epigenetic, and developmental programs that drive lung carcinoids remain obscure, limiting our abilities to suggest new biomarkers and drug targets.

Aim(s): Systematic characterization of cis-regulatory elements and transcription in typical and atypical lung carcinoids, and validation of candidate inhibitors in-vitro and in-vivo.

Materials and methods: We profiled for the first time genome-wide maps of cis-regulatory elements of primary lung carcinoids by H3K27ac ChIP-seq and RNA-seq. We tested CDK7/9 or FGF inhibition in cell lines and in a mouse xenograft model.

Conference:

Presenting Author: Drier Y

Authors: Davis E, Avniel-Polak S, Hecht M, Grozinsky-Glasberg S, Drier Y,

Keywords: FGF Signaling, Lung carcinoids, Enhancers,